{"name":"Nippon Shinyaku","slug":"nippon-shinyaku","ticker":"4516.T","exchange":"TSE","domain":"nippon-shinyaku.co.jp","description":"Nippon Shinyaku Co., Ltd. is a Japanese pharmaceutical company headquartered in Kyoto that develops, manufactures, and markets prescription drugs and functional foods. Founded in 1911, the company initially focused on herbal medicines before expanding into modern pharmaceuticals, with current therapeutic areas including urology, hematology, intractable and rare diseases, and gynecology. Nippon Shinyaku is listed on the Tokyo Stock Exchange and has developed treatments such as viltolarsen for Duchenne muscular dystrophy.","hq":"Kyoto, Japan","founded":1949,"employees":"2243","ceo":"Toru Nakai","sector":"Rare Disease / Pulmonary Hypertension","stockPrice":4117,"stockChange":-58,"stockChangePercent":-1.39,"marketCap":"$1.8B","metrics":{"revenue":1049827451.0428078,"revenueGrowth":13.1,"grossMargin":67.3,"rdSpend":0,"netIncome":188725767.2436183,"cash":384222911.47259086,"dividendYield":2.97,"peRatio":8.7,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1969-01-01","label":"Cytarabine first approved","drug":"Cytarabine","drugSlug":"cytarabine","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Viltepso first approved","drug":"Viltepso","drugSlug":"viltolarsen","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Ono-2121 patent cliff ($1.2B at risk)","drug":"Ono-2121","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Ono-2123 patent cliff ($800M at risk)","drug":"Ono-2123","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Cytarabine","genericName":"Cytarabine","slug":"cytarabine","indication":"Acute lymphoid leukemia","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Viltepso","genericName":"VILTOLARSEN","slug":"viltolarsen","indication":"Duchenne muscular dystrophy","status":"marketed"}]}],"pipeline":[{"name":"Cytarabine","genericName":"Cytarabine","slug":"cytarabine","phase":"marketed","mechanism":"Cytarabine inhibits DNA polymerase and incorporates into DNA/RNA, killing cells in S-phase.","indications":["Acute lymphoid leukemia","Acute myeloid leukemia, disease","Acute promyelocytic leukemia, FAB M3","Lymphomatous meningitis","Meningeal Leukemia"],"catalyst":""},{"name":"Viltepso","genericName":"VILTOLARSEN","slug":"viltolarsen","phase":"marketed","mechanism":"Viltepso works by binding to exon 53 of dystrophin pre-mRNA, allowing for the production of a partially functional dystrophin protein.","indications":["Duchenne muscular dystrophy"],"catalyst":""}],"recentEvents":[{"date":"2022-03-31","type":"earnings","headline":"Nippon Shinyaku Reports FY2021 Financial Results","summary":"The company reported a net income of ¥12.1 billion for the fiscal year 2021, up 10% from the previous year.","drugName":"","sentiment":"positive"},{"date":"2020-12-18","type":"deal","headline":"Nippon Shinyaku Partners with University of Tokyo to Develop New Treatment for Pulmonary Hypertension","summary":"The partnership aims to develop a novel treatment for pulmonary hypertension using a proprietary technology.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2025-12-04","type":"pipeline","source":"simplywall.st","summary":"Nippon Shinyaku Co., Ltd. (TSE:4516) Stock Catapults 32% Though Its Price And Business Still Lag The Market - simplywall.st","headline":"Nippon Shinyaku Co., Ltd. (TSE:4516) Stock Catapults 32% Though Its Price And Business Still Lag The Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE0tSzNnQ01CRS1Pb2YxYjNTMFBBTjJ6SXM2NW94dDVOYnRHM3h4c1RsajRjV1NacHpZOFZtRDdMeXpNekZrS3prZ3pOMjZJVXpfNEJMMA?oc=5","date":"2019-11-04","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Fuji Pharma Co., Ltd. (4554.T) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Fuji Pharma Co., Ltd. (4554.T) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Ono-2121","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"Ono-2123","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":800000000}],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Takeda Pharmaceutical","Eisai Co., Ltd.","Shionogi & Co., Ltd."],"therapeuticFocus":["Rare Diseases","Pulmonary Hypertension"],"financials":{"source":"yahoo_finance","revenue":1013062237.3648,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":1013062237.3648},{"period":"2024-03-31","value":937337997.407},{"period":"2023-03-31","value":911542314.0949999},{"period":"2022-03-31","value":869238657.9576}],"grossProfit":689876466.811,"grossProfitHistory":[{"period":"2025-03-31","value":689876466.811},{"period":"2024-03-31","value":619734969.0993999},{"period":"2023-03-31","value":557610365.123},{"period":"2022-03-31","value":551907495.9202}],"rdSpend":217119990.34739998,"rdSpendHistory":[{"period":"2025-03-31","value":217119990.34739998},{"period":"2024-03-31","value":200270604.0664},{"period":"2023-03-31","value":152592847.239},{"period":"2022-03-31","value":144550663.6182}],"sgaSpend":240323460.3854,"operatingIncome":224137933.6014,"operatingIncomeHistory":[{"period":"2025-03-31","value":224137933.6014},{"period":"2024-03-31","value":210519330.2058},{"period":"2023-03-31","value":189990265.57},{"period":"2022-03-31","value":208312787.68719998}],"netIncome":205847023.8412,"netIncomeHistory":[{"period":"2025-03-31","value":205847023.8412},{"period":"2024-03-31","value":163442208.1614},{"period":"2023-03-31","value":144228217.5768},{"period":"2022-03-31","value":157973270.40039998}],"eps":483.4,"epsHistory":[{"period":"2025-03-31","value":483.4},{"period":"2024-03-31","value":383.82},{"period":"2023-03-31","value":338.7},{"period":"2022-03-31","value":370.97}],"cash":349259642.6074,"cashHistory":[{"period":"2025-03-31","value":349259642.6074},{"period":"2024-03-31","value":367297653.51159996},{"period":"2023-03-31","value":379645440.1558},{"period":"2022-03-31","value":382926802.8124}],"totalAssets":1793286820.4817998,"totalLiabilities":229493066.87719998,"totalDebt":17209767.1508,"equity":1561821142.5277998,"operatingCashflow":228405601.79639998,"operatingCashflowHistory":[{"period":"2025-03-31","value":228405601.79639998},{"period":"2024-03-31","value":102986736.6346},{"period":"2023-03-31","value":165459076.538},{"period":"2022-03-31","value":134769800.3624}],"capex":-219977747.4202,"capexHistory":[{"period":"2025-03-31","value":-219977747.4202},{"period":"2024-03-31","value":-61005526.5386},{"period":"2023-03-31","value":-74149944.5792},{"period":"2022-03-31","value":-56541861.7302}],"freeCashflow":8427854.3762,"dividendsPaid":-52779991.2472,"buybacks":-6322.471399999999,"employees":2243,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":null,"ebitda":null,"period":"2025-06-30","revenue":null,"epsBasic":122.52,"netIncome":null,"rdExpense":null,"epsDiluted":122.52,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":4117,"previousClose":4175,"fiftyTwoWeekHigh":6529,"fiftyTwoWeekLow":2967,"fiftyTwoWeekRange":"2967.0 - 6529.0","fiftyDayAverage":5025,"twoHundredDayAverage":4387.35,"beta":0,"enterpriseValue":1413021556.387083,"forwardPE":10,"priceToBook":0.98,"priceToSales":1.67,"enterpriseToRevenue":1.35,"enterpriseToEbitda":5.21,"pegRatio":0,"ebitda":271177132.5519069,"ebitdaMargin":25.8,"freeCashflow":31688225.03824732,"operatingCashflow":196015586.0744962,"totalDebt":16103335.06043817,"debtToEquity":0.9,"currentRatio":5.64,"returnOnAssets":7.4,"returnOnEquity":11.2,"analystRating":"2.6 - Hold","recommendationKey":"hold","numberOfAnalysts":7,"targetMeanPrice":5457.14,"targetHighPrice":8200,"targetLowPrice":2600,"dividendRate":124,"payoutRatio":0.26,"fiveYearAvgDividendYield":2.31,"exDividendDate":1774828800,"insiderHeldPercent":4.7,"institutionHeldPercent":49.7,"sharesOutstanding":67400949,"floatShares":62773200,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":473.86,"epsForward":410.59,"revenuePerShare":2465.28,"bookValue":4211.78,"officers":[{"age":54,"name":"Mr. Toru  Nakai","title":"President & Director"},{"age":null,"name":"Mr. Hideyuki  Fujii","title":"Accounting & Finance Department Manager"},{"age":null,"name":"Manabu  Beppu","title":"Corporate Officer and Head of R & D Planning and Administration Div."},{"age":65,"name":"Mr. Takashi  Takaya","title":"GM of Personnel, General Affairs, Risk Mgmt, Compliance & Digital Trans and Director"},{"age":59,"name":"Kazuyuki  Iwata","title":"Director of Sales and Marketing & Director"},{"age":null,"name":"Yoko  Nakanishi","title":"Corporate Officer & Department Manager of Human Resources Dept."},{"age":62,"name":"Mr. Takanori  Edamitsu","title":"Head of Business Management & Sustainability and Director"},{"age":64,"name":"Mr. Hitoshi  Ishizawa","title":"GM of Functional Food Division & Director"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.nippon-shinyaku.co.jp","phone":"81 7 5321 1111"}}